Charles Cotropia

Director

CHARLES S. COTROPIA is CEO of Enzolytics, Inc., a Texas based biotech company with technology for treating infectious diseases. Through a business combination between Enzolytics and BioClonetics Immunotherapeutics, the Company is now advancing two separate but complimentary technology platforms focusing on therapeutics for treating HIV and the CoronaVirus.

One technology is a patented antiviral peptide that has been tested in clinical studies at the National Center of Infectious and Parasitic Diseases in Bulgaria. In these clinical trials, the therapeutic, known as ITV-1, demonstrated effectiveness in the treatment of HIV patients in various stages of the disease.

A separate technology applies a proprietary methodology for producing fully human IgG1 monoclonal antibodies for treating infectious diseases with non-toxic passive immunotherapy. From this methodology, the company has created proprietary cell lines that produce fully human monoclonal antibodies that target and neutralize infectious diseases including HIV, influenza, tetanus and diphtheria. Using this technology, the company has developed a monoclonal antibody that has been demonstrated in tests in 5 independent laboratories to fully neutralize over 95% of the HIV isolates against which it was tested.

In conjunction with advancing these therapeutics targeting HIV, the Company is applying its methodology to produce fully human monoclonal antibodies targeting the CoronaVirus. This work is being conducted in the company’s lab on the Texas A&M University campus at the TAMU Institute for Preclinical Studies.

Prior to his current position, Charles served CEO and Chairman of the Board of BioClonetics.

He has previously served as a partner and senior counsel at Sidley Austin LLP in its Dallas office. Charles has over 40 years of litigation experience having handled cases in Federal Court involving patents, trademarks, trade dress, unfair competition and copyrights. As an intellectual property attorney, he served as lead counsel in patent, trademark, trade dress and copyright disputes litigated in federal courts and the United States Patent and Trademark Office. Charles represented clients with products and services in many diverse areas, including biotechnology, aerospace, electronics, the Internet and the oil and gas industry.

Connect on LinkedIn